TriWise Capital
20
36M
16
2.22
3
0.20
1
- Areas of investment
Summary
TriWise Capital appeared to be the VC, which was created in 2015. The company was established in Asia in China. The main office of represented VC is situated in the Shenzhen.
The fund was created by Dajie Tang.
The high activity for fund was in 2017. The common things for fund are deals in the range of 10 - 50 millions dollars. The fund is generally included in less than 2 deals every year.
The usual cause for the fund is to invest in rounds with 3-4 partakers. Despite the TriWise Capital, startups are often financed by Shenzhen Capital Group, ShenZhen GTJA Investment Group, Qianhai Xino. The meaningful sponsors for the fund in investment in the same round are Shenzhen Capital Group, ShenZhen GTJA Investment Group, Qianhai Fund of Funds. In the next rounds fund is usually obtained by Sino Biopharmaceutical, Shenzhen Capital Group, Loyal Valley Capital.
For fund there is a match between the country of its foundation and the country of its the most frequent investments - China. We can highlight the next thriving fund investment areas, such as Therapeutics, Health Care. Among the various public portfolio startups of the fund, we may underline Akeso Biopharma Moreover, a startup needs to be at the age of 4-5 years to get the investment from the fund.
Investments analytics
Analytics
- Total investments
- 20
- Lead investments
- 3
- Exits
- 1
- Rounds per year
- 2.22
- Follow on index
- 0.20
- Investments by industry
- Health Care (12)
- Biotechnology (9)
- Medical (6)
- Biopharma (5)
- Pharmaceutical (4) Show 10 more
- Investments by region
-
- China (18)
- United States (1)
- Peak activity year
- 2023
Discover reliable insights
Leverage validated data, identify key contacts and secure funding opportunities for your business.Quantitative data
- Avg. startup age at the time of investment
- 6
- Group Appearance index
- 1.00
Need more data?
Get access to full data about investors, including their team, contact information, and historic data.
Latest deals
| Company name | Deal date | Industry | Deal stage | Deal size | Location |
|---|---|---|---|---|---|
| BiyoPharma | 26 Apr 2024 | Seed | |||
| Coordinate | 04 Jun 2020 | Software, Information Technology, Computer, Consulting | Seed | 232K | Yorkshire and the Humber, Sheffield, United Kingdom |
| Innoforce Pharmaceuticals | 06 Dec 2021 | Health Care, Pharmaceutical | Early Stage Venture | 57M | Hangzhou, Zhejiang, China |
| ZIPDOC | 12 Apr 2016 | Interior Design, Home Renovation | Seed | 113K | South Korea, Gyeonggi-do |
At Unicorn Nest, we combine cutting-edge technology with human expertise to build one of the most reliable venture capital databases in the market. Our process begins with automated AI-enhanced data collection, leveraging the full potential of Large Language Models (LLMs).
Later, our team of analysts takes it further with manual verification, using proprietary tools for data cleaning and validation to ensure accuracy and reliability. We cross-check and enhance our findings through press and media monitoring, integrating information from trusted news outlets and venture capital aggregators. Finally, we stay ahead of the curve by monitoring social networks like LinkedIn and X.com.